Denali Therapeutics Inc. DNLI Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $390.73M+87.5% | $208.43M+122% | $94.07M-34.8% | $144.31M+140% | $60.05M-66.0% | ||
| $600.06M-9.4% | $662.55M-12.5% | $757.24M-0.1% | $757.75M-0.4% | $760.98M+15.8% | ||
| $1.02B+13.6% | $900.66M+2.0% | $882.6M-5.6% | $934.71M+6.4% | $878.64M+1.6% | ||
| $51.73M-1.3% | $52.4M-2.5% | $53.73M-8.5% | $58.72M+1.6% | $57.77M+4.6% | ||
| $36M— | $0— | —— | —— | —— | ||
| $1.27B+10.6% | $1.14B+8.5% | $1.06B-9.5% | $1.17B-8.3% | $1.27B-7.5% | ||
| $40.38M+7,896% | $505K-92.5% | $6.75M-37.8% | $10.84M+28.2% | $8.46M-24.1% | ||
| $90K+8.4% | $83K— | —— | —— | —— | ||
| $110.16M+12.0% | $98.35M+9.1% | $90.15M-1.0% | $91.06M-0.9% | $91.88M-10.1% | ||
| $339.93M+159% | $131.09M+1.3% | $129.42M-7.0% | $139.19M-6.4% | $148.66M+2.9% | ||
| $1.91M+1.3% | $1.89M+5.3% | $1.79M+0.6% | $1.78M+0.3% | $1.78M+0.6% | ||
| -$2.18B-6.3% | -$2.05B-6.7% | -$1.92B-7.1% | -$1.8B-7.4% | -$1.67B-8.6% | ||
| $926.1M-8.6% | $1.01B+9.5% | $926.2M-9.8% | $1.03B-8.5% | $1.12B-8.7% | ||
| $1.27B+10.6% | $1.14B+8.5% | $1.06B-9.5% | $1.17B-8.3% | $1.27B-7.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Denali Therapeutics Inc. cover its short-term obligations?
- Its current ratio is 9.28 — current assets exceed current liabilities.
- Where does Denali Therapeutics Inc.'s balance sheet data come from?
- Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.